@article{22848b7cb3ae44f4ba2e9f2d0fd02c49,
title = "Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer",
keywords = "chemotherapy, docetaxel, prostate cancer, chemotherapy, docetaxel, prostate cancer",
author = "Petteri Hervonen and Heikki Joensuu and Timo Joensuu and Claes Ginman and Ray McDermott and Ulrika Harmenberg and Paul Nyandoto and Tiina Luukkaala and Akseli Hemminki and Igor Zaitsev and Mirja Heikkinen and Sten Nilsson and Marjaana Luukkaa and Ilari Lehtinen and Pirkko-Liisa Kellokumpu-Lehtinen",
year = "2012",
language = "English",
volume = "32",
pages = "953--956",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",
}